Alnylam Pharmaceuticals revenue and financials
$223.94Change from previous close: +1.84%Absolute change: +$4.05
In the fiscal year ended December 2025, Alnylam Pharmaceuticals reported revenue of $3.71B (+65.19% year over year). Net income was $313.75M, a net margin of 8.4%.
Fiscal year ending in December. Sources and method on the page Methodology and sources.
At a glance
- Revenue growth
- +65.19%
- 2025 vs 2024
- Net margin
- 8.4%
- 2024: -12.4%
Financial data
Amounts in millions of USD; per-share values in USD; shares in millions.
| Item | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | 327 | 70.5 | 164 | 325 | 130 | -120 | -94.7 | 43.7 | 124 | -81.5 | -29.8 | 359 |
| Depreciation and amortization | 13.9 | 13.6 | 13.5 | 13.8 | 13.9 | 14.4 | 14.2 | 14.0 | 15.0 | 13.5 | -19.0 | 23.5 |
| Capital expenditure | -34.7 | -21.8 | -23.3 | -12.1 | -14.3 | -9.0 | -9.1 | -4.2 | -8.0 | -13.0 | -15.3 | -17.1 |
| Investing cash flow | -363 | -25.5 | -37.2 | 501 | -141 | 114 | -52.9 | -30.3 | 33.9 | -67.6 | -241 | -10.8 |
| Financing cash flow | 36.2 | 15.7 | 45.3 | -448 | 77.7 | 46.1 | 31.0 | 103 | 131 | 28.9 | 39.2 | 33.1 |
| Debt issued | — | — | -0.7 | 646 | — | — | — | — | — | — | — | — |
| Debt repaid | — | — | -52.3 | -1,140 | — | — | — | — | — | — | — | — |
| Effect of exchange rates | -2.4 | -7.1 | -5.7 | -0.9 | 27.5 | 14.1 | -17.3 | 15.1 | -3.1 | -9.9 | 10.9 | -6.6 |
| Net change in cash | -2.9 | 53.6 | 166 | 377 | 93.6 | 53.6 | -134 | 131 | 286 | -130 | -220 | 375 |
| Free cash flow | 292 | 48.7 | 140 | 313 | 116 | -129 | -104 | 39.5 | 116 | -94.5 | -45.1 | 342 |
| Levered free cash flow | 189 | -5.9 | -44.9 | 108 | 122 | -81.8 | -75.6 | 95.4 | 273 | -94.7 | -41.6 | 223 |